サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：サイコバイオティクス市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018-2028年
市場調査レポート
商品コード
1321048

サイコバイオティクス市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018-2028年

Psychobiotics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Psychotropic Agent, By Form, By Application, By Region and Competition

出版日
ページ情報
英文 110 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

サイコバイオティクス市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018-2028年
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 110 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のサイコバイオティクス市場は、予測期間2024-2028年に驚異的な成長を遂げると予測されています。

市場の成長は、特にストレス、不安、睡眠障害などの精神衛生問題に対する懸念の高まりに起因すると考えられます。Global Burden of Diseases, Injuries, and Risk Factors Study（GBD）2019によると、不安障害とうつ病障害は、最も無力な2つの精神疾患であり、2019年の世界の疾病負担の主要原因の上位25位に入っています。この負担は、男女を問わず、世界中で軒並み重かっています。おそらくより重大なことは、その影響を軽減する治療法の強力な証拠があるにもかかわらず、どちらの障害も世界の有病率や負担が減少していないことです。加えて、COVID-19の突然の発生と、2020年から2021年にかけて世界各国でウイルスを抑制するために実施される封鎖措置により、人々の間で精神衛生上の問題が増加しています。

不安とうつ病を治療するプロバイオティクスの需要増加

微生物-腸-脳軸に影響を与えることで、プロバイオティクスは気分と宿主の健康に影響を与えることができます。ストレス、不安、うつ病はすべて、感情が徐々に希薄化することに関係しています。不安はストレスに対する反応であるが、それが持続し、治療法を誤ると、うつ病のようなより深刻な精神疾患に発展する可能性があります。ストレスは通常、肉体的または精神的に負担のかかるさまざまな出来事や、緊急の状況に対する短時間の反応から生じる。多くの研究が、人々の不安とうつ病の間に微妙な関係があることを発見しています。オーストラリアのデータによると、臨床的に重大な不安を抱える患者の28％がうつ病を併発しており、うつ病患者の約57％が不安も併発していました。

いくつかの調査によると、腸内細菌叢が気分の調節に積極的な役割を果たしていることが証明されており、プロバイオティクスは幅広い用途で利用されています。いくつかの研究によると、大うつ病性障害の被験者では、プロテオバクテリア、バクテロイデーテス、およびアクチノバクテリアの量が増加し、一方ファーミキューテスの量は著しく減少しました。プロバイオティクスは中枢神経系の活動や行動にさまざまな影響を及ぼします。まず、一部の局在細菌は、宿主細胞によるセロトニン、ドーパミン、GABAなどの神経伝達物質の産生を誘導することができます。さらに、微生物は脳の神経伝達物質受容体の発現を変化させることができます。抗炎症性サイトカインを増加させ、炎症性サイトカインを減少させることで、プロバイオティクスは全身の炎症抑制にも役立ちます。

プロバイオティクスが精神疾患に有効であるという事実を踏まえ、ストレス、不安、うつ病などの精神疾患の治療におけるプロバイオティクスの応用を研究する臨床試験の数も急増しています。したがって、このことは今後数年間の世界のサイコバイオティクス市場の拡大にさらに貢献しています。

不安とうつ病の急増

人々に最も頻繁に影響を与える2つの精神疾患は、うつ病と不安障害です。気分障害の主な種類の1つであるうつ病は、気分の落ち込みと興味の喪失が特徴で、罪悪感、絶望感、食欲不振、不眠を伴うことが多いです。不安は、緊張感、心配、恐怖のほか、動悸、震え、消化器系、呼吸器系、循環器系の問題など、明確な客観的理由のない身体的変化を伴う。世界保健機関（WHO）の推計によると、2015年には不安障害が3.6％、うつ病が4.4％の世界人口に影響を及ぼすと予測されています。

COVID-19パンデミックは、世界中の患者のメンタルヘルスにも最悪の影響を及ぼしました。Lancet』誌に発表された研究によると、不安障害の発症率は全世界で男女ともに25.6％増加しました。うつ病の有病率は27.6％増加しました。両疾患の有病率の増加は、男性よりも女性で顕著に大きかっています。うつ病の有病率は女性で29.8％増加したのに対し、不安障害の有病率は女性で27.9％、男性で21.7％増加しました。

消費者意識の高まり

市場の成長は、消費者の消化を含む身体全般のプロセスを改善するサイコバイオティクス学的能力によっても促進されると予想されます。また、胃腸や免疫系など特定の消費者の需要に対応するサイコバイオティクスの能力や、製品開発における最近の進歩の結果、需要も増加すると予測されます。

ケリー・グループが2019年に健康志向の米国人2,100人を対象に実施した世界の世論調査によると、回答者の62％がプロバイオティクスが何であるかを知っており、32％が過去6カ月間に使用したことがあっています。プロバイオティクスを知っているアメリカ人の79％が、消化器系の健康改善が製品に求める最も重要な健康効果であると回答しました。

さらに、メーカー各社は、新しい形状、食事条件、パッケージの革新的なサイコバイオティクス関連製品の開発に力を入れています。メーカーによるビーガンやグルテンフリーのサイコバイオティクス製品のイントロダクションより、健康志向でビーガンの消費者の間でサイコバイオティクスの需要が高まっています。そのため、改善された健康的なライフスタイルのためにプロバイオティクスを生活に取り入れる人が増えています。このことは、予測される数年間で、サイコバイオティクス産業を増強する可能性が高いです。

利用可能なカスタマイズ

TechSciリサーチは、与えられた市場データを用いて、企業の特定のニーズに応じてカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場企業の概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向の概要

第4章 顧客の声

  • ブランド認知度
  • 好みの購入方法
  • 精神疾患の主な要因
  • サイコバイオティクス製品に対する消費意欲
  • 摂取後に観察される一般的な心理学的効果

第5章 臨床試験分析

第6章 特許分析

第7章 サイコバイオティクスの世界市場展望

  • 市場規模と予測
    • 金額・数量別
  • 市場シェアと予測
    • サイコバイオティクス別
    • 形態別
    • 用途別
    • 地域別
    • 企業別
  • 製品市場マップ
    • サイコバイオティクス別
    • 形態別
    • 用途別
    • 地域別
  • 価格分析

第8章 北米のサイコバイオティクス市場の展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • サイコバイオティクス別
    • 形態別
    • 用途別
    • 国別
  • 価格分析
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 欧州のサイコバイオティクス市場展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • サイコバイオティクス別
    • 形態別
    • 用途別
    • 国別
  • 価格分析
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン
    • スウェーデン
    • ポーランド
    • スロバキア

第10章 アジア太平洋地域のサイコバイオティクス市場展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • サイコバイオティクス別
    • 形態別
    • 用途別
    • 国別
  • 価格分析
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア
    • 台湾
    • マレーシア
    • シンガポール

第11章 南米のサイコバイオティクス市場展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • サイコバイオティクス別
    • 形態別
    • 用途別
    • 国別
  • 価格分析
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第12章 中東・アフリカのサイコバイオティクス市場展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • サイコバイオティクス別
    • 形態別
    • 用途別
    • 国別
  • 価格分析
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第13章 市場力学

  • 促進要因
    • 不安とうつ病に対するプロバイオティクスの使用の増加
    • 不安とうつ病患者の急増
    • 若者の自己診断とセルフメディケーションの傾向
  • 課題
    • 身体的健康への悪影響
    • 内分泌および代謝への副作用
    • 新興諸国および低開発諸国における入手不可能性

第14章 市場動向と発展

  • 臨床試験数の増加
  • 競合の激化と今後の技術革新
  • 合併と買収

第15章 競合情勢

  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（As Reported）
  • Recent Developments
  • SWOT Analysis
    • InnovixLabs
    • Bened Biomedical Co., Ltd
    • Nutrimmun GmbH
    • Kerry Group Plc.
    • Sabinsa Corporation
    • Lallemand Health Solutions Inc.
    • DuPont de Nemours, Inc.
    • Uplift Food Pty Ltd.
    • Nature's Bounty Co. Ltd.
    • BioGaia Group
    • The Life Extension Foundation
    • Lifted Naturals

第16章 戦略的提言

目次
Product Code: 7678

Global Psychobiotics market is projected to accomplish extraordinary growth in the forecast period, 2024-2028. The market growth can be attributed to the rising concerns about mental health problems such as stress, anxiety, and sleep disorders, among others. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, anxiety and depression disorders were the two most incapacitating mental diseases, ranking among the top 25 primary causes of disease burden globally in 2019. This burden was heavy across the board, for both sexes, across the globe. Perhaps more crucially, despite strong evidence of therapies that lessen their impact, no decline in either disorder's global prevalence or burden has been observed. Additionally, the sudden outbreak of COVID-19 and the imposition of lockdown to curb the virus in 2020-2021 across different countries around the globe has increased mental health issues among the population.

A unique category of probiotics known as Psychobiotics helps people maintain their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although there are not many products available in the market, health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotic market in the future.

Increasing Demand for Probiotics to Treat Anxiety and Depression

By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.

Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes, and Actinobacteria were increased in subjects with major depressive disorders, whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters, including serotonin, dopamine, and GABA, by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines-a pattern connected to the control of intestinal permeability-probiotics also assist in reducing systemic inflammation.

Given the fact that probiotics benefit psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety, and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotic market in the upcoming years.

Surge in Cases of Anxiety and Depression

The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression, is characterized by poor mood and loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common, and depression was estimated to affect up to 4.4% of the world's population in 2015.

The COVID-19 pandemic also displayed its worst impacts on the mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression, whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.

Rising Consumer Awareness

The market's growth is also anticipated to be fueled by the psychobiotic capacity to improve the body's general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.

According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were, and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.

In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, the demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotic industry in the forecasted years.

Market Segmentation

Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agents, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.

Company Profiles

Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.

Report Scope

In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Psychobiotics Market, By Psychotropic Agent:

  • Streptococcus
  • Bifidobacterium
  • Lactobacillus
  • Clostridium
  • Others

Psychobiotics Market, By Form:

  • Powder
  • Liquid/Fluid
  • Tablets
  • Others

Psychobiotics Market, By Application:

  • Stress Management
  • Mood Health & Mood Upliftment
  • Depression
  • Anxiety
  • Sleep Problems
  • Others

Psychobiotics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
    • Sweden
    • Poland
    • Slovakia
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Taiwan
    • Malaysia
    • Singapore
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Brand Awareness
  • 4.2. Preferred Mode of Purchase
  • 4.3. Major Factors Contributing to Mental Illness
  • 4.4. Willingness towards Psychobiotics Consumption
  • 4.5. Commonly Observed Psychological Effect Post Consumption

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Patents Analysis

7. Global Psychobiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Product Market Map
    • 7.3.1. By Psychotropic Agent
    • 7.3.2. By Form
    • 7.3.3. By Application
    • 7.3.4. By Region
  • 7.4. Pricing Analysis

8. North America Psychobiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 8.2.4. By Country
  • 8.3. Pricing Analysis
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Psychobiotics Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value & Volume
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Psychotropic Agent
        • 8.4.1.2.2. By Form
        • 8.4.1.2.3. By Application
      • 8.4.1.3. Pricing Analysis
    • 8.4.2. Mexico Psychobiotics Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value & Volume
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Psychotropic Agent
        • 8.4.2.2.2. By Form
        • 8.4.2.2.3. By Application
      • 8.4.2.3. Pricing Analysis
    • 8.4.3. Canada Psychobiotics Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value & Volume
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Psychotropic Agent
        • 8.4.3.2.2. By Form
        • 8.4.3.2.3. By Application
      • 8.4.3.3. Pricing Analysis

9. Europe Psychobiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 9.2.4. By Country
  • 9.3. Pricing Analysis
  • 9.4. Europe: Country Analysis
    • 9.4.1. France Psychobiotics Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value & Volume
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Psychotropic Agent
        • 9.4.1.2.2. By Form
        • 9.4.1.2.3. By Application
      • 9.4.1.3. Pricing Analysis
    • 9.4.2. Germany Psychobiotics Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value & Volume
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Psychotropic Agent
        • 9.4.2.2.2. By Form
        • 9.4.2.2.3. By Application
      • 9.4.2.3. Pricing Analysis
    • 9.4.3. United Kingdom Psychobiotics Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value & Volume
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Psychotropic Agent
        • 9.4.3.2.2. By Form
        • 9.4.3.2.3. By Application
      • 9.4.3.3. Pricing Analysis
    • 9.4.4. Italy Psychobiotics Market Outlook
      • 9.4.4.1. Market Size & Forecast
        • 9.4.4.1.1. By Value & Volume
      • 9.4.4.2. Market Share & Forecast
        • 9.4.4.2.1. By Psychotropic Agent
        • 9.4.4.2.2. By Form
        • 9.4.4.2.3. By Application
      • 9.4.4.3. Pricing Analysis
    • 9.4.5. Spain Psychobiotics Market Outlook
      • 9.4.5.1. Market Size & Forecast
        • 9.4.5.1.1. By Value & Volume
      • 9.4.5.2. Market Share & Forecast
        • 9.4.5.2.1. By Psychotropic Agent
        • 9.4.5.2.2. By Form
        • 9.4.5.2.3. By Application
      • 9.4.5.3. Pricing Analysis
    • 9.4.6. Sweden Psychobiotics Market Outlook
      • 9.4.6.1. Market Size & Forecast
        • 9.4.6.1.1. By Value & Volume
      • 9.4.6.2. Market Share & Forecast
        • 9.4.6.2.1. By Psychotropic Agent
        • 9.4.6.2.2. By Form
        • 9.4.6.2.3. By Application
      • 9.4.6.3. Pricing Analysis
    • 9.4.7. Poland Psychobiotics Market Outlook
      • 9.4.7.1. Market Size & Forecast
        • 9.4.7.1.1. By Value & Volume
      • 9.4.7.2. Market Share & Forecast
        • 9.4.7.2.1. By Psychotropic Agent
        • 9.4.7.2.2. By Form
        • 9.4.7.2.3. By Application
      • 9.4.7.3. Pricing Analysis
    • 9.4.8. Slovakia Psychobiotics Market Outlook
      • 9.4.8.1. Market Size & Forecast
        • 9.4.8.1.1. By Value & Volume
      • 9.4.8.2. Market Share & Forecast
        • 9.4.8.2.1. By Psychotropic Agent
        • 9.4.8.2.2. By Form
        • 9.4.8.2.3. By Application
      • 9.4.8.3. Pricing Analysis

10. Asia-Pacific Psychobiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 10.2.4. By Country
  • 10.3. Pricing Analysis
  • 10.4. Asia-Pacific: Country Analysis
    • 10.4.1. China Psychobiotics Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value & Volume
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Psychotropic Agent
        • 10.4.1.2.2. By Form
        • 10.4.1.2.3. By Application
      • 10.4.1.3. Pricing Analysis
    • 10.4.2. India Psychobiotics Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value & Volume
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Psychotropic Agent
        • 10.4.2.2.2. By Form
        • 10.4.2.2.3. By Application
      • 10.4.2.3. Pricing Analysis
    • 10.4.3. South Korea Psychobiotics Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value & Volume
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Psychotropic Agent
        • 10.4.3.2.2. By Form
        • 10.4.3.2.3. By Application
      • 10.4.3.3. Pricing Analysis
    • 10.4.4. Japan Psychobiotics Market Outlook
      • 10.4.4.1. Market Size & Forecast
        • 10.4.4.1.1. By Value & Volume
      • 10.4.4.2. Market Share & Forecast
        • 10.4.4.2.1. By Psychotropic Agent
        • 10.4.4.2.2. By Form
        • 10.4.4.2.3. By Application
      • 10.4.4.3. Pricing Analysis
    • 10.4.5. Australia Psychobiotics Market Outlook
      • 10.4.5.1. Market Size & Forecast
        • 10.4.5.1.1. By Value & Volume
      • 10.4.5.2. Market Share & Forecast
        • 10.4.5.2.1. By Psychotropic Agent
        • 10.4.5.2.2. By Form
        • 10.4.5.2.3. By Application
      • 10.4.5.3. Pricing Analysis
    • 10.4.6. Taiwan Psychobiotics Market Outlook
      • 10.4.6.1. Market Size & Forecast
        • 10.4.6.1.1. By Value & Volume
      • 10.4.6.2. Market Share & Forecast
        • 10.4.6.2.1. By Psychotropic Agent
        • 10.4.6.2.2. By Form
        • 10.4.6.2.3. By Application
      • 10.4.6.3. Pricing Analysis
    • 10.4.7. Malaysia Psychobiotics Market Outlook
      • 10.4.7.1. Market Size & Forecast
        • 10.4.7.1.1. By Value & Volume
      • 10.4.7.2. Market Share & Forecast
        • 10.4.7.2.1. By Psychotropic Agent
        • 10.4.7.2.2. By Form
        • 10.4.7.2.3. By Application
      • 10.4.7.3. Pricing Analysis
    • 10.4.8. Singapore Psychobiotics Market Outlook
      • 10.4.8.1. Market Size & Forecast
        • 10.4.8.1.1. By Value & Volume
      • 10.4.8.2. Market Share & Forecast
        • 10.4.8.2.1. By Psychotropic Agent
        • 10.4.8.2.2. By Form
        • 10.4.8.2.3. By Application
      • 10.4.8.3. Pricing Analysis

11. South America Psychobiotics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 11.2.4. By Country
  • 11.3. Pricing Analysis
  • 11.4. South America: Country Analysis
    • 11.4.1. Brazil Psychobiotics Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value & Volume
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Psychotropic Agent
        • 11.4.1.2.2. By Form
        • 11.4.1.2.3. By Application
      • 11.4.1.3. Pricing Analysis
    • 11.4.2. Argentina Psychobiotics Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value & Volume
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Psychotropic Agent
        • 11.4.2.2.2. By Form
        • 11.4.2.2.3. By Application
      • 11.4.2.3. Pricing Analysis
    • 11.4.3. Colombia Psychobiotics Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value & Volume
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Psychotropic Agent
        • 11.4.3.2.2. By Form
        • 11.4.3.2.3. By Application
      • 11.4.3.3. Pricing Analysis

12. Middle East and Africa Psychobiotics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 12.2.4. By Country
  • 12.3. Pricing Analysis
  • 12.4. MEA: Country Analysis
    • 12.4.1. South Africa Psychobiotics Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value & Volume
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Psychotropic Agent
        • 12.4.1.2.2. By Form
        • 12.4.1.2.3. By Application
      • 12.4.1.3. Pricing Analysis
    • 12.4.2. Saudi Arabia Psychobiotics Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value & Volume
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Psychotropic Agent
        • 12.4.2.2.2. By Form
        • 12.4.2.2.3. By Application
      • 12.4.2.3. Pricing Analysis
    • 12.4.3. UAE Psychobiotics Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value & Volume
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Psychotropic Agent
        • 12.4.3.2.2. By Form
        • 12.4.3.2.3. By Application
      • 12.4.3.3. Pricing Analysis

13. Market Dynamics

  • 13.1. Drivers
    • 13.1.1. Increased Use of Probiotics for Anxiety and Depression
    • 13.1.2. Surge in Subjects with Anxiety and Depression
    • 13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
  • 13.2. Challenges
    • 13.2.1. Detrimental Effects on Physical Health
    • 13.2.2. Endocrine and Metabolic Side Effects
    • 13.2.3. Unavailability in Developing Countries and Under-Developed Countries

14. Market Trends & Developments

  • 14.1. Increasing Number of Clinical Trials
  • 14.2. Increased Competition and Upcoming Innovations
  • 14.3. Mergers & Acquisitions

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As Reported)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. InnovixLabs
    • 15.6.2. Bened Biomedical Co., Ltd
    • 15.6.3. Nutrimmun GmbH
    • 15.6.4. Kerry Group Plc.
    • 15.6.5. Sabinsa Corporation
    • 15.6.6. Lallemand Health Solutions Inc.
    • 15.6.7. DuPont de Nemours, Inc.
    • 15.6.8. Uplift Food Pty Ltd.
    • 15.6.9. Nature's Bounty Co. Ltd.
    • 15.6.10. BioGaia Group
    • 15.6.11. The Life Extension Foundation
    • 15.6.12. Lifted Naturals

16. Strategic Recommendations